News | September 28, 2011

Resverglogix Study Examines Atherosclerotic Plaque Regression Drug

September 28, 2011 — A clinical trial by Resverlogix Corp. is evaluating the early effects of a new drug compound in atherosclerotic plaque regression. The study is focused on patients with coronary artery disease who have a low level of high-density lipoprotein cholesterol (HDL-C).

The company said study sites for the Phase 2b ApoA-l Synthesis Stimulation in Acute Coronary Syndrome (ASSURE) clinical trial have now been activated; the goal is to examine the early effects of RVX-208 induced ApoA-I production on plaque regression. A total of 310 patients are expected to participate, of which 77 will receive placebo and 233 will be given 100 mg twice daily of RVX-208.

This step opens the door for patient enrollment in ASSURE, a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial; it will assess coronary atherosclerotic plaque changes in response to Resverlogix’s RVX-208 using intravascular ultrasound (IVUS).

The primary endpoint will be IVUS measurement of a change in percent atheroma volume from baseline to 26 weeks. Secondary objectives are: (i) safety and tolerability of RVX-208 as reflected by adverse events, and (ii) effects of RVX-208 on HDL and non-HDL lipid parameters.

Enrollment is expected to be complete by the end of the year. The study chair is Steven Nissen, M.D., chairman of the Cleveland Clinic department of cardiovascular medicine. The principal investigator for the trial is Stephen Nicholls, M.D., medical director of intravascular ultrasound at Cleveland Clinic.

"The ASSURE protocol arose from valuable knowledge gained in our Phase 2 ASSERT trial. In ASSERT, subjects given RVX-208 had; (i) a dose dependent and sustained increase in ApoA-l levels, (ii) a significant rise in HDL-C, especially alpha-1 particles or functional HDL, and (iii) a highly statistically significant increase in large HDL particles. These pronounced changes in the HDL profile arises from the initial RVX-208 induced increase in ApoA-I production and these changes in HDL point to enhanced RCT which in turn gives rise to the potential for atherosclerotic plaque regression," stated Jan Johansson, M.D., senior vice president of medical affairs.

"Furthermore, we were encouraged by the dose-response relationship for lowering of hyper sensitive C-reactive protein (hs-CRP), also suggesting a beneficial effect on the artery wall," Johansson added.

For more information:


Related Content

Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals | March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
Overlay Init